Results 61 to 70 of about 49,350 (169)

A case of tri-segmental cranial nerve V herpes zoster

IDCases, 2019
Varicella-zoster is the causative virus underlying varicella or “chickenpox” and herpes zoster or “shingles.” Cases of disseminated disease have been widely reported in immunocompromised patients.
Hena S. Cheema, Aloise M. Diedrich, Briana M. Kyne, Mona Toeque   +3 more
doaj   +1 more source

Genital Herpes Zoster in an Immunocompetent Adult: A Rare Presentation

JEADV Clinical Practice, EarlyView.
Sunil Jaiswal, Shraddha Uprety, Pratichya Thapa, Aditi Joshi, Prakriti Lamichhane   +4 more
wiley   +1 more source

Rationale for Recommending Varicella Vaccination Into the Swedish National Immunisation Programme

Acta Paediatrica, EarlyView.
ABSTRACT Aim Under Swedish law, a vaccination may be included in the National Immunisation Programme (NIP) if it effectively prevents transmission in the population, is cost‐effective and aligns with ethical and humanitarian principles. The Public Health Agency of Sweden (PHAS) evaluated these criteria for introducing varicella vaccination. Methods The
Annika Ersson, Kari Johansen, Sören Andersson   +2 more
wiley   +1 more source

A Zosteriform Papular Cutaneous Eruption

JEADV Clinical Practice, EarlyView.
Silvia Borriello, Umberto Santaniello, Astrid Lappi, Paolo Borrelli, Angelo Battaglia, Roberta Patetta, Sophie Frassy, Simone Ribero, Pietro Quaglino   +8 more
wiley   +1 more source

Health Economic Evaluation of Varicella Vaccination Within the Swedish National Vaccination Programme for Children

Acta Paediatrica, EarlyView.
ABSTRACT Aim To assess the cost‐effectiveness of including varicella vaccination in the Swedish national vaccination programme for children together with the added impact of catch‐up vaccination of susceptible older children. Methods An epidemiological transmission model was used to assess the cost‐effectiveness of a two‐dose national varicella ...
Frida Kasteng, Gianpaolo Scalia Tomba, Annika Ersson, Ellen Wolff, Sören Andersson, Kari Johansen   +5 more
wiley   +1 more source

MRD‐negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD‐positive after first‐line therapy: Final analysis of the open‐label, single‐arm multicentric phase 2 trial DART4MM

British Journal of Haematology, EarlyView.
In newly diagnosed multiple myeloma patients in ≥Very Good Partial Remission (VGPR) after a first‐line therapy daratumumab as consolidation/maintenance improved long‐term minimal residual disease negativity. Summary Daratumumab is approved for front‐line and relapsed myeloma therapy.
Alessandro Gozzetti, Paola Pacelli, Federico Caroni, Donatella Raspadori, Elena Bestoso, Elisabetta Antonioli, Gabriele Buda, Sara Ciofini, Adele Santoni, Luca Puccetti, Francesca Bacchiarri, Ludovica Pengue, Dania Tocci, Irene Attucci, Maria Livia del Giudice, Miriana Ruggieri, Alessandra Lombardo, Anna Marina Liberati, Veronica Candi, Vincenzo Sammartano, Alessandra Cartocci, Anna Sicuranza, Sara Galimberti, Alessandro Maria Vannucchi, Monica Bocchia   +24 more
wiley   +1 more source

No increased risk of herpes zoster found in cirrhotic patients: a nationwide population-based study in Taiwan.

PLoS ONE, 2014
BackgroundThe association between liver cirrhosis (LC) and herpes zoster has rarely been studied. We investigated the hypothesis that LC, known as an immunodeficiency disease, may increase the risk of herpes zoster using a national health insurance ...
Ping-Hsun Wu, Yi-Ting Lin, Chun-Nan Kuo, Wei-Chiao Chang, Wei-Pin Chang   +4 more
doaj   +1 more source

Refractory Lichen Amyloidosis Coexisting With Atopic Dermatitis Responsive to Sequential Janus Kinase Inhibitor Therapy: Upadacitinib Followed by Abrocitinib

The Kaohsiung Journal of Medical Sciences, EarlyView.
Yu‐Ting Tsai, Jui Lan, Shang‐Hung Lin   +2 more
wiley   +1 more source

Tafasitamab as Monotherapy or in Combination in Japanese Patients With B‐Cell Non‐Hodgkin Lymphoma: Results From the Phase 1b J‐MIND Study

Cancer Science, EarlyView.
J‐MIND evaluated the safety and tolerability of tafasitamab, a CD19‐targeting monoclonal antibody, alone or in combination with other therapies in Japanese patients with B‐cell non‐Hodgkin lymphoma (NHL). Most common treatment‐emergent adverse events across all groups were hematological, and no serious tafasitamab treatment‐related or fatal adverse ...
Koji Izutsu, Noriko Fukuhara, Junichiro Yuda, Youko Suehiro, Shigeru Kusumoto, Marie‐Laure Casadebaig, Kazumi Suzukawa, Kentaro Fukushima   +7 more
wiley   +1 more source

Herpes zóster dúplex

Medicina Clínica Práctica, 2020
Marta Martínez-García, Nicolás Silvestre-Torner, Adrián Imbernón-Moya, Hirune Cembrero-Saralegui   +3 more
doaj   +1 more source